Lan Chem Laboratories is a commercial stage biopharmaceuticall group focused on produces: toothpaste, shower gels, mint teas and ginger tea and other personal health care products. The Group has identified important and commercially attractive unmet needs in nausea & vomiting and procedural sedation, and has two approved products and a late-stage development candidate in its portfolio designed to meet those needs.
We aim to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy.
The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address. Lan Chem Laboratories's portfolio comprises:
(intravenous amisulpride): approved in the UK (February 2020) for the treatment and prophylaxis of postoperative nausea & vomiting (PONV) either alone or incombination with antiemetics of a different class.
(remimazolam) for injection: a very rapid onset/offset benzodiazepine sedative approved in the UK (July 2020) for use during invasive medical procedures lasting 30 minutes or less, such as colonoscopy and bronchoscopy.
(intravenous and oral amisulpride): a selective dopamine antagonist in Phase 2 for chemotherapy induced nausea & vomiting (CINV).
Lan Chem Laboratories has its own commercial infrastructure in the UK through which it will sell its products directly.
Lan Chem Laboratories intends to establish licensing and/or distribution agreements with selected pharmaceutical partners outside the UK for Barhemsys® and APD403.
The Company’s management team and Board have extensive experience in the development and commercialization of hospital pharmaceutical products.
Lan Chem Laboratories was founded in 2007 and has offices in Armagh, UK.